论文部分内容阅读
目的检测中介素(Intermedin)在人子宫内膜腺癌组织中的表达,探讨其表达与子宫内膜腺癌临床病理参数以及微血管密度(MVD)的关系。方法应用免疫组化方法检测中介素在子宫内膜单纯性增生、子宫内膜不典型增生和子宫内膜腺癌组织中的表达,通过免疫组化SP法检测组织内微血管密度(MVD),比较中介素表达与肿瘤微血管密度的关系。结果中介素在子宫内膜腺癌中的表达高于子宫内膜单纯性增生及不典型增生中的表达;在子宫内膜腺癌中,中介素的表达与肿瘤的临床FIGO分期呈正相关(P=0.018),与肿瘤的肌层浸润呈正相关(P=0.0004)。中介素的表达与肿瘤的MVD呈正相关(P=0.002)。结论中介素在子宫内膜腺癌的发生发展过程中起到促进作用,并参与肿瘤血管生成。
Objective To detect the expression of Intermedin in human endometrial adenocarcinoma and to explore its relationship with clinicopathological parameters and microvessel density (MVD) in endometrial adenocarcinoma. Methods Immunohistochemical method was used to detect the expression of interleukin (IL) in endometrial hyperplasia, endometrial dysplasia and endometrial adenocarcinoma. Immunohistochemical SP method was used to detect the microvessel density (MVD) Relationship between Interleukin Expression and Tumor Microvessel Density. Results The expression of interleukin in endometrial adenocarcinoma was higher than that in endometrial hyperplasia and atypical hyperplasia. In endometrial adenocarcinoma, the expression of interleukin was positively correlated with the clinical FIGO stage (P = 0.018), which was positively correlated with myometrial invasion (P = 0.0004). Interleukin expression was positively correlated with tumor MVD (P = 0.002). Conclusion Interleukin plays an important role in the development of endometrial adenocarcinoma and is involved in tumor angiogenesis.